ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Gilead teams with Nurix for protein degradation

by Lisa M. Jarvis
June 22, 2019 | APPEARED IN VOLUME 97, ISSUE 25

 

Gilead Sciences will pay Nurix Therapeutics $45 million up front to collaborate on targeted protein degradation therapies for cancer and other diseases. Whereas conventional small-molecule drugs block the function of a protein, Nurix’s compounds can break down the protein altogether. The biotech firm’s technology harnesses enzymes called E3 ligases that dictate when a protein gets broken down in the cell. Under the multiyear pact, Gilead can license drug candidates against five undisclosed protein targets.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment